Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Anthony R MatoJennifer A WoyachJennifer R BrownPaolo GhiaKrish PatelToby A EyreTalha MunirEwa Lech-MarandaNicole LamannaConstantine S TamNirav N ShahCatherine C CoombsChaitra S UjjaniBita FakhriChan Yoon Y CheahManish R PatelAlvaro J AlencarJonathon B CohenJames N GersonIan W FlinnShuo MaDeepa JagadeeshJoanna M RhodesFrancisco Hernandez-IlizaliturriPier L ZinzaniJohn Francis SeymourMinna BalbasBinoj NairPaolo AbadaChunxiao WangAmy S RuppertDenise WangDonald E TsaiWilliam G WierdaWojciech JurczakPublished in: The New England journal of medicine (2023)
In this trial, pirtobrutinib showed efficacy in patients with heavily pretreated CLL or SLL who had received a covalent BTK inhibitor. The most common adverse events were infections, bleeding, and neutropenia. (Funded by Loxo Oncology; BRUIN ClinicalTrials.gov number, NCT03740529.).